411 related articles for article (PubMed ID: 25443889)
21. Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil.
Perdaems N; Blasco H; Vinson C; Chenel M; Whalley S; Cazade F; Bouzom F
Clin Pharmacokinet; 2010 Apr; 49(4):239-58. PubMed ID: 20214408
[TBL] [Abstract][Full Text] [Related]
22. Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator.
Wang K; Yao X; Zhang M; Liu D; Gao Y; Sahasranaman S; Ou YC
CPT Pharmacometrics Syst Pharmacol; 2021 May; 10(5):441-454. PubMed ID: 33687157
[TBL] [Abstract][Full Text] [Related]
23. Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug-Drug Interactions in Children.
Cleary Y; Kletzl H; Grimsey P; Heinig K; Ogungbenro K; Silber Baumann HE; Frey N; Aarons L; Galetin A; Gertz M
Clin Pharmacokinet; 2023 Jun; 62(6):891-904. PubMed ID: 37148485
[TBL] [Abstract][Full Text] [Related]
24. Drug-drug interaction potential of marketed oncology drugs: in vitro assessment of time-dependent cytochrome P450 inhibition, reactive metabolite formation and drug-drug interaction prediction.
Kenny JR; Mukadam S; Zhang C; Tay S; Collins C; Galetin A; Khojasteh SC
Pharm Res; 2012 Jul; 29(7):1960-76. PubMed ID: 22415140
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Nguyen L; Holland J; Miles D; Engel C; Benrimoh N; O'Reilly T; Lacy S
J Clin Pharmacol; 2015 Sep; 55(9):1012-23. PubMed ID: 25854986
[TBL] [Abstract][Full Text] [Related]
26. Critical Impact of Drug-Drug Interactions via Intestinal CYP3A in the Risk Assessment of Weak Perpetrators Using Physiologically Based Pharmacokinetic Models.
Yamada M; Inoue SI; Sugiyama D; Nishiya Y; Ishizuka T; Watanabe A; Watanabe K; Yamashita S; Watanabe N
Drug Metab Dispos; 2020 Apr; 48(4):288-296. PubMed ID: 31996361
[TBL] [Abstract][Full Text] [Related]
27. A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.
Frechen S; Junge L; Saari TI; Suleiman AA; Rokitta D; Neuvonen PJ; Olkkola KT; Fuhr U
Clin Pharmacokinet; 2013 Sep; 52(9):763-81. PubMed ID: 23653047
[TBL] [Abstract][Full Text] [Related]
28. Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A/P‑glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover.
Qian CQ; Zhao KJ; Chen Y; Liu L; Liu XD
Eur J Pharm Sci; 2019 Jun; 134():194-204. PubMed ID: 31047967
[TBL] [Abstract][Full Text] [Related]
29. Examination of CYP3A and P-glycoprotein-mediated drug-drug interactions using animal models.
Marathe PH; Rodrigues AD
Methods Mol Biol; 2010; 596():385-403. PubMed ID: 19949933
[TBL] [Abstract][Full Text] [Related]
30. Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database: high utilization of drugs with interaction potential.
Lauffenburger JC; Mayer CL; Hawke RL; Brouwer KL; Fried MW; Farley JF
Eur J Gastroenterol Hepatol; 2014 Oct; 26(10):1073-82. PubMed ID: 25014625
[TBL] [Abstract][Full Text] [Related]
31. Quantitative Prediction of the Effect of CYP3A Inhibitors and Inducers on Venetoclax Pharmacokinetics Using a Physiologically Based Pharmacokinetic Model.
Freise KJ; Shebley M; Salem AH
J Clin Pharmacol; 2017 Jun; 57(6):796-804. PubMed ID: 28052338
[TBL] [Abstract][Full Text] [Related]
32. Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.
Umeyama Y; Fujioka Y; Okuda T
Xenobiotica; 2014 Dec; 44(12):1135-44. PubMed ID: 24937160
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data.
Einolf HJ; Chen L; Fahmi OA; Gibson CR; Obach RS; Shebley M; Silva J; Sinz MW; Unadkat JD; Zhang L; Zhao P
Clin Pharmacol Ther; 2014 Feb; 95(2):179-88. PubMed ID: 23995268
[TBL] [Abstract][Full Text] [Related]
34. Simulations of Cytochrome P450 3A4-Mediated Drug-Drug Interactions by Simple Two-Compartment Model-Assisted Static Method.
Iga K; Kiriyama A
J Pharm Sci; 2017 May; 106(5):1426-1438. PubMed ID: 28089686
[TBL] [Abstract][Full Text] [Related]
35. Structure-Property Relationships and Machine Learning Models for Addressing CYP3A4-Mediated Victim Drug-Drug Interaction Risk in Drug Discovery.
Hu B; Zhou X; Mohutsky MA; Desai PV
Mol Pharm; 2020 Sep; 17(9):3600-3608. PubMed ID: 32794756
[TBL] [Abstract][Full Text] [Related]
36. Drug-drug interactions via mechanism-based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation.
Venkatakrishnan K; Obach RS
Curr Drug Metab; 2007 Jun; 8(5):449-62. PubMed ID: 17584016
[TBL] [Abstract][Full Text] [Related]
37. Alternatives to rifampicin: A review and perspectives on the choice of strong CYP3A inducers for clinical drug-drug interaction studies.
Bolleddula J; Gopalakrishnan S; Hu P; Dong J; Venkatakrishnan K
Clin Transl Sci; 2022 Sep; 15(9):2075-2095. PubMed ID: 35722783
[TBL] [Abstract][Full Text] [Related]
38. Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process.
Watanabe A; Nakamura K; Okudaira N; Okazaki O; Sudo K
Drug Metab Dispos; 2007 Jul; 35(7):1232-8. PubMed ID: 17392390
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetic Interaction of Rifampicin with Oral Versus Intravenous Anticancer Drugs: Challenges, Dilemmas and Paradoxical Effects Due to Multiple Mechanisms.
Srinivas NR
Drugs R D; 2016 Jun; 16(2):141-8. PubMed ID: 27098526
[TBL] [Abstract][Full Text] [Related]
40. Analysis of Clinical Drug-Drug Interaction Data To Predict Magnitudes of Uncharacterized Interactions between Antiretroviral Drugs and Comedications.
Stader F; Kinvig H; Battegay M; Khoo S; Owen A; Siccardi M; Marzolini C
Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29686151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
